LINCMECAR is Baiti Biotech's in vivo CAR-T/M technology system built on the tpLNP targeted delivery platform, targeting refractory and relapsed diseases including oncology, fibrosis and autoimmune conditions. Collaborative research services are available.
| 体系构成 | tpLNP 递送平台 + 体内 CAR-T/M 构建与评价 |
|---|---|
| 研究重点 | 靶向递送效率、体内重编程、机制与安全性 |
| 疾病方向 | 肿瘤、纤维化、自身免疫等难治性复发型疾病 |
| 合作形式 | 联合开发、机制研究与技术合作 |
公司公开的 2025 年度回顾中提及 LINCMECAR® 技术体系全链条优化;相关临床研究已在国际注册(ClinicalTrials.gov,以登记编号为准)。
Sources: Baiti Biotech official site (www.100biotech.com), patent publications and ClinicalTrials.gov registrations. Updated 2026-11-21.
Baiti Biotech is an AI for Science medical research technology service company. It provides research technology services and collaborative research, not clinical treatment for patients.